These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 20129212)

  • 1. ACE-inhibition and physical function: results from the Trial of Angiotensin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study.
    Cesari M; Pedone C; Incalzi RA; Pahor M
    J Am Med Dir Assoc; 2010 Jan; 11(1):26-32. PubMed ID: 20129212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study.
    Cesari M; Kritchevsky SB; Atkinson HH; Penninx BW; Di Bari M; Tracy RP; Pahor M
    Am Heart J; 2009 Feb; 157(2):334.e1-8. PubMed ID: 19185642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ACE-inhibition on IGF-1 and IGFBP-3 concentrations in older adults with high cardiovascular risk profile.
    Giovannini S; Cesari M; Marzetti E; Leeuwenburgh C; Maggio M; Pahor M
    J Nutr Health Aging; 2010 Jun; 14(6):457-60. PubMed ID: 20617288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled trial of angiotensin-converting enzyme inhibition for skeletal muscle dysfunction in COPD.
    Shrikrishna D; Tanner RJ; Lee JY; Natanek A; Lewis A; Murphy PB; Hart N; Moxham J; Montgomery HE; Kemp PR; Polkey MI; Hopkinson NS
    Chest; 2014 Oct; 146(4):932-940. PubMed ID: 24556825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of tissue affinity of angiotensin-converting enzyme inhibitors on left ventricular remodeling after myocardial infarction.
    Konermann M; Altmann C; Laschewski F; Josephs W; Odenthal HJ; Horstmann E; Sanner B
    Clin Cardiol; 1998 Apr; 21(4):277-85. PubMed ID: 9562938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
    Atthobari J; Asselbergs FW; Boersma C; de Vries R; Hillege HL; van Gilst WH; Gansevoort RT; de Jong PE; de Jong-van den Berg LT; Postma MJ;
    Clin Ther; 2006 Mar; 28(3):432-44. PubMed ID: 16750458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skeletal muscle angiotensin-converting enzyme and its relationship to blood pressure in primary hypertension and healthy elderly men.
    Reneland R; Haenni A; Andersson PE; Andrén B; Lithell H
    Blood Press; 1999; 8(1):16-22. PubMed ID: 10412878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOSIDIAL: a randomised placebo controlled trial of the effects of fosinopril on cardiovascular morbidity and mortality in haemodialysis patients. Study design and patients' baseline characteristics.
    Zannad F; Kessler M; Grünfeld JP; Thuilliez C;
    Fundam Clin Pharmacol; 2002 Oct; 16(5):353-60. PubMed ID: 12602460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of peripheral microvascular dysfunction during long-term treatment with the angiotensin-converting enzyme inhibitor fosinopril in congestive heart failure.
    Galatius S; Wroblewski H; Sørensen V; Haunsø S; Nørgaard T; Kastrup J
    J Card Fail; 1999 Mar; 5(1):17-24. PubMed ID: 10194656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma endothelin in congestive heart failure: effect of the ACE inhibitor, fosinopril.
    Galatius-Jensen S; Wroblewski H; Emmeluth C; Bie P; Haunsø S; Kastrup J
    Cardiovasc Res; 1996 Dec; 32(6):1148-54. PubMed ID: 9015418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.
    Asselbergs FW; Diercks GF; Hillege HL; van Boven AJ; Janssen WM; Voors AA; de Zeeuw D; de Jong PE; van Veldhuisen DJ; van Gilst WH;
    Circulation; 2004 Nov; 110(18):2809-16. PubMed ID: 15492322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fosinopril versus enalapril in the treatment of hypertension: a double-blind study in 195 patients.
    Hansson L; Forslund T; Höglund C; Istad H; Lederballe-Pedersen O; Kristinsson A; Segaard E; Svensson A; Aärynen M; Wahrenberg H; Wennersten G; Kjellström T
    J Cardiovasc Pharmacol; 1996 Jul; 28(1):1-5. PubMed ID: 8797128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a fixed-dose ACE inhibitor-diuretic combination on ambulatory blood pressure and arterial properties in isolated systolic hypertension.
    Ferguson JM; Minas J; Siapantas S; Komesaroff PA; Sudhir K
    J Cardiovasc Pharmacol; 2008 Jun; 51(6):590-5. PubMed ID: 18520951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do ACE inhibitors improve the response to exercise training in functionally impaired older adults? A randomized controlled trial.
    Sumukadas D; Band M; Miller S; Cvoro V; Witham M; Struthers A; McConnachie A; Lloyd SM; McMurdo M
    J Gerontol A Biol Sci Med Sci; 2014 Jun; 69(6):736-43. PubMed ID: 24201696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Microalbuminuria--an independent indication for administration of ACE inhibitors: role of fosinopril (PREVEND IT trial)].
    Ter Arkh; 2005; 77(9):84-8. PubMed ID: 16281498
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of fosinopril treatment on serum C-reactive protein levels in patients with microalbuminuria.
    van der Harst P; Asselbergs FW; Hillege HL; Voors AA; van Veldhuisen DJ; van Gilst WH;
    Am J Cardiol; 2008 Jul; 102(2):223-5. PubMed ID: 18602526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans.
    Massien C; Azizi M; Guyene TT; Vesterqvist O; Mangold B; Ménard J
    Clin Pharmacol Ther; 1999 Apr; 65(4):448-59. PubMed ID: 10223783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The angiotensin converting enzyme inhibitors fosinopril and enalapril differ in their central nervous effects in humans.
    Derad I; Otterbein A; Mölle M; Pietrowsky R; Born J; Fehm HL
    J Hypertens; 1996 Nov; 14(11):1309-15. PubMed ID: 8934359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitor index: a novel method for measuring pharmacological inhibition of angiotensin-converting enzyme.
    Reneland R; Lithell H
    Blood Press; 1997 Mar; 6(2):103-8. PubMed ID: 9105649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Centrally Acting ACE Inhibitor Use and Physical Performance in Older Adults.
    George CJ; Hall CB; Weiss EF; Verghese J; Neptune E; Abadir P
    J Frailty Aging; 2023; 12(2):103-108. PubMed ID: 36946705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.